Oral Presentation

A Ghosh, G Nucci, N Haddish-Berhane, T Maurer, D Tess, D Chen, Y Chen, P DaSilva-Jardine, A Lo, M Reed, J Bosley, R Baillie

A Systems Approach to Accelerating the Pharmaceutical Industry Pipeline

Presented by Pfizer and Rosa at 6th International Symposium on Measurement & Kinetics of In Vivo Drug Effects, 2010

Poster

A Dunton, M Feldman, K Matsuda, BM Sadler, J Bosley, R Beaver

Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling and Simulation Support the Novelty of MN-221, a Highly-Selective Beta2-Adrenergic Agonist for Treatment of Acute Asthma.

Presented by MediciNova and Rosa at American College of Chest Physicians Annual Meeting (CHEST), 2010

Poster

R Baillie, A Dunton, M Feldman, K Matsuda, BM Sadler, J Bosley, E Kitt, R Beaver

PK/PD Modeling of MN-221 for COPD and Acute Asthma

Presented by MediciNova and Rosa at Cambridge Health Institute (CHI) Discovery on Target (DOT): COPD, 2010

Oral Presentation

R Baillie, A Dunton, M Feldman, K Matsuda, BM Sadler, J Bosley, E Kitt, R Beaver

MN‑221, a Novel Beta2-Adrenergic Agonist for Treatment of Acute Asthma and COPD

Presented by MediciNova and Rosa at Cambridge Health Institute (CHI) Discovery on Target (DOT): COPD, 2010

Poster

R Baillie, J Bosley, C Friedrich

Modeling Glucose Metabolism in Diabetes

Presented by Pfizer and Rosa at Cambridge Healthtech Institute, Discovery on Target (CHI-DOT): Diabetes, 2010

Poster

J Bosley, R Baillie

Modeling an antibody therapeutic

Presented by Rosa at the Quantitative & Systems Pharmacology Workshop II, National Institute of General Medical Sciences (NIGMS), 2010

Oral Presentation

A Ghosh, G Nucci, N Haddish-Berhane, T Maurer, D Tess, D Chen, Y Chen, P DaSilva-Jardine, A Lo, M Reed, J Bosley, R Baillie

Systems Approaches to Modeling Diabetes within Pfizer With Applications to SGLT2i and Modeling Glucose Metabolism in Diabetes

Presented by Pfizer and Rosa at Cambridge Healthtech Institute (CHI) Discovery on Target (DOT), 2010

"I am grateful to our many clients who have challenged us over the past 15 years to conduct PhysioPD Research on the frontier of science."
—Ron Beaver, PhD, Founder, CEO
Learn more about PhysioPD